Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Rangering i aksjer #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Aksjekurs
$62.26
Sist synkronisert: 2026-09-22
Markedsverdi
$127.18B
Endring (1 dag)
-0.78%
Endring (1 år)
38.63%
Land
US
Handel Bristol-Myers Squibb Company (BMY)

Kategori

Inntekter for Bristol-Myers Squibb Company (BMY)
Inntekter i Jun 2026 TTM: $49.19B
Ifølge de nyeste økonomiske rapportene til Bristol-Myers Squibb Company er selskapets nåværende inntekter (TTM) $49.19B. I 2024 hadde selskapet inntekter på $48.30B en økning sammenlignet med inntektene i 2023, som var $45.01B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Bristol-Myers Squibb Company fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $49.19B 2.06%
2025 $48.19B -0.22%
2024 $48.30B 7.32%
2023 $45.01B -2.50%
2022 $46.16B -0.49%
2021 $46.39B 9.09%
2020 $42.52B 62.62%
2019 $26.15B 15.89%
2018 $22.56B 8.59%
2017 $20.78B 6.94%
2016 $19.43B 17.31%
2015 $16.56B 4.29%
2014 $15.88B -3.09%
2013 $16.39B -7.01%
2012 $17.62B -17.05%
2011 $21.24B 9.03%
2010 $19.48B 3.59%
2009 $18.81B -8.69%
2008 $20.60B 6.46%
2007 $19.35B 8.00%
2006 $17.91B -6.73%
2005 $19.21B -0.89%
2004 $19.38B -7.25%
2003 $20.89B 15.32%
2002 $18.12B -6.71%
2001 $19.42B 6.63%
2000 $18.22B 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$79.67B 61.97%
US
$97.93B 99.10%
US
$64.39B 30.90%
US
$77.52B 57.60%
CH
$66.40B 35.00%
US